Cornerstone Robotics Shines Bright at ELSA2023, Latest Robotics Technology Captivates Attention

Hong Kong, Oct 13, 2023 – (ACN Newswire) – Cornerstone Robotics (CSR or the Company) is a leading company in Chinese surgical robotics industry. We are delighted to share that the Founder and CEO of CSR, Professor Samuel Au, was invited to participate and deliver a speech at the 16th Asia-Pacific Congress of Endoscopic & Laparoscopic Surgeons of Asia 2023 (ELSA 2023) in Istanbul on 5-7th October.

Prof. Samuel Au delivered a speech on Surgical Robotics in the Future: Forging Accessibility in Robotic Surgery. With the rapid development of AI, imaging, and robotic technologies, robotic-assisted surgery has reshaped the landscape of medical diagnosis and treatment solutions. These technological breakthroughs allow better visualization, higher precision, and greater accessibility for minimally invasive surgery. In other words, robotic surgery has become increasingly accessible to more surgeons, benefiting patients worldwide.

Prof. Samuel Au is also the Director of Multi-Scale Medical Robotics Center (MRC), a world-class research hub standing at the forefront of global innovation. “MRC brings the worlds of medicine and robotics together, with a focus on technological innovation and a strong emphasis on clinical translation and direct patient benefits”, he remarked. The Center supports three research programs, namely endoluminal multi-scale robotic platforms for diagnostics and therapeutics, magnetic-guided endoluminal robotic platforms, and image-guided robotic interventions.

Founded in 2019, Cornerstone Robotics is committed to developing, producing, and distributing high-quality surgical robots. The company has assembled an international team of surgical robotics experts and clinical professionals from a diverse range of disciplines. To accelerate growth, CSR has established key innovation hubs in Beijing, Shanghai, Shenzhen, Hong Kong, and Boston.

In his speech, Prof. Samuel Au introduced the C1000 Endoscopic Surgical System, which was developed entirely in-house. Fitted with articulating instruments, the C1000 system enables operations to be performed with precision and dexterity. With the lightweight surgeon controls, tremor filtration, and motion smoothing techniques, surgeons can perform delicate and complex surgeries in confined spaces.

CSR and its cutting-edge technology have captivated attention and earned recognition among international experts. CSR aspires to be a global supplier of safe and efficient surgical robots. Fueled by its vision, the company is committed to forging accessibility in robotic surgeries and benefiting surgeons and patients worldwide.

Dr. LIANG Xiao of SRRSH Invited as ELSA 2023 Sole Keynote Speaker from Mainland China

Hong Kong, Oct 11, 2023 – (ACN Newswire) – The 16th Asia Pacific Congress of Endoscopic & Laparoscopic Surgeons of Asia 2023 (“ELSA 2023”) was held in Istanbul, Turkey, from October 5th to 7th. The conference featured a comprehensive and diverse range of activities, including live surgeries, roundtable meetings, and technical laboratory research, bringing together approximately 75 prestigious experts from around the world to deliver keynote speeches, with over a thousand scholars in attendance. Among them, Dr. LIANG Xiao, Assistant Director of Qiantang Campus and Deputy Director of General Surgery at the Sir Run Run Shaw Hospital (“SRRSH” or “Hospital”), affiliated with the Zhejiang University School of Medicine, was the only expert from mainland China invited to deliver a keynote speech and host a workshop at the conference.

Dr. LIANG Xiao delivered a speech titled “New Era of Minimally Invasive Surgery for Hepatocellular Carcinoma in China”, sharing the latest and significant technological advancements in minimally invasive surgery with the audience. With great enthusiasm, Dr. LIANG introduced SRRSH, which is dedicated to promoting and applying minimally invasive surgical techniques. The Hospital is one of the leading institutions in China with the broadest range of minimally invasive surgical procedures and involvement in various disciplines. Its numerous clinical research and applications in surgery have reached an internationally advanced level.

During its nearly 30 years of operation, SRRSH has embraced change, innovation, and the development of a modern and internationalized “Shaw Hospital Model.” It has also adopted the advanced “Internet + Healthcare” service model. With Dr. CAI Xiujun, the President of SRRSH, leading the way, the Hospital has progressed steadily, achieving remarkable results.

Besides establishing China’s first secondary discipline in “Minimally Invasive”, SRRSH’s Department of General Surgery has achieved notable recognition. In the “2022 Science and Technology Evaluation Matrix Rankings for Chinese Hospitals” organized by the Chinese Academy of Medical Sciences, it emerged as the 12th best among over 1,600 hospitals nationwide, receiving industry recognition and acclaim.

The Hospital has also founded China’s first international journal on minimally invasive surgery, with Dr. CAI, the President of SRRSH, as the editor-in-chief. The journal has received recognition by being selected for the “China Science and Technology Journal Excellence Action Plan” by seven ministries, including the China Association for Science and Technology and the Chinese Academy of Sciences, among others. Several international academic websites have also indexed the journal. As one of the doctors at the Hospital, Dr. LIANG has actively engaged in parallel initiatives, including establishing the Chinese Laparoscopic Hepatobiliary Surgery Academy and organizing nationally recognized continuing education programs for training purposes.

During the speech, Dr. LIANG also introduced the “Cai’s ALPPS” surgical technique, which Dr. CAI independently developed. The technique features a unique and innovative surgical approach, combined with minimally invasive surgery that effectively blocks the blood flow between the left and right liver lobes, completely resolving complications. This approach also minimizes patient trauma and accelerates postoperative recovery processes.

Dr. LIANG also showcased several short videos highlighting robot-assisted surgeries, demonstrating the precise and flexible surgical techniques performed in confined spaces. He presented multiple professional literature and data excerpts that indicate robot-assisted surgery, compared to laparoscopic surgery, effectively reduces patient bleeding and surgical risks while maximizing the preservation of healthy liver tissue. Additionally, it helps minimize postoperative complications and shorten recovery time. This presentation attracted the attention of overseas experts and scholars, further increasing their interest in the innovative technologies and development of minimally invasive surgical techniques in China.

Chinese medical enterprises have actively responded to the call of the government and made great efforts to promote domestic medical technology research and development. The development of domestically produced surgical robots in China has been progressing rapidly, with continuous advancements in technology and accuracy. During his speech, Dr. LIANG specifically mentioned and acknowledged certain companies, including Cornerstone Robotics. With the growing number of clinical trials conducted by domestic companies and experts, he believes that domestically produced surgical robots will be a significant trend in future minimally invasive surgery in China. They are expected to lead liver surgeries into a new era, benefiting the medical industry and the general public.

New Frontier Group Achieves ISO 9001 Certification

FOOTHILL RANCH, CA, Oct 10, 2023 – (ACN Newswire) – New Frontier Group, a cost management leader in global healthcare for over 21 years, is proud to announce that it has been awarded the ISO 9001 Certification. This internationally recognized standard affirms the company’s unwavering commitment to delivering the highest quality products/services and its dedication to continual improvement in its operational processes.

ISO 9001 is a globally respected standard for quality management systems, awarded to organizations that can consistently provide products and services that meet customer and applicable statutory and regulatory requirements. The certification also indicates the organization’s dedication to enhancing customer satisfaction through the effective application of the system, including processes for improvement and the assurance of conformity to customer and applicable statutory and regulatory requirements.

“We are thrilled to achieve this milestone,” said Gitte Bach CEO of New Frontier Group. “Obtaining the ISO 9001 Certification is a testament to our team’s hard work and the high standards we set for ourselves. Our clients can be even more confident in our ability to deliver consistent quality and our commitment to continually refine our processes.”

The certification process involved a rigorous external audit of New Frontier Group’s operational processes, ensuring compliance with the international standards set by the ISO organization. This process underscored the company’s dedication to maintaining the highest levels of customer satisfaction.

About New Frontier Group

New Frontier Group is a global cost management leader. The company is a woman business enterprise unrivaled for the range of solutions in international healthcare management and unbeatable in their hallmark customer and claim service. They are a front-line outsourcing partner and advocate for clients handling diverse healthcare travel portfolios.

For inquiries, contact CEO Gitte Bach, President and CEO:
bach@newfrontiergroup.com (949) 429-7130 www.newfrontiergroup.com

Contact Information:
Peggy Johnson, Marketing Consultant, peggy@hypesmith.com 317.514.5318
Reghan Robinson, Project Manager, reghan@hypesmith.com 850.776.1299

A closer examination at JinMed’s top-line growth trajectory, revealing an abundance growth potential

Hong Kong, Oct 10, 2023 – (ACN Newswire) – With the positive indications in the US stock market, Chinese concept stocks have gotten significant attention. Among them, Jin Medical International Ltd. (“JinMed” or the “Company”, NASDAQ: ZJYL), a emerging player in the medical equipment sector, delivered exceptional performance that exceeded industry benchmarks last month. In addition to receiving market recognition of its wheelchair business, there is even greater anticipation regarding the company’s strategic development and management team’s execution capabilities.

Upon closer examination of JinMed’s recent financial performance, its revenue is not as undesirable as recently discussed. Despite a slight decrease in revenue for the fiscal year 2022 compared to the fiscal year 2021, there was still a commendable growth of 19% compared to the fiscal year 2020. This achievement is particularly noteworthy given the stringent policies and trade measures implemented during the COVID-19 pandemic in 2022, underscoring JinMed’s clear overall revenue growth trend.

Taking a further examining at this interim report following the easing of the pandemic, while the report reveals a year-on-year revenue growth of only 8.3% and a net profit growth of 44.1% for the first half of 2023, it is important to consider that the financial report is denominated in US dollars, without factoring in the impact of foreign exchange gains or losses. In reality, excluding external factors, JinMed witnessed an impressive increase by 18.7% and net profit by 57.9% during the first half of the fiscal year 2023, signifying its consistent out-performance industry average growth the past three years.

After analyzing the revenue performance, let us delve into the growth prospects. The aging population in both China and Japan has created a consistent demand for medical assistive devices, particularly wheelchairs. According to a report by Frost & Sullivan, the total sales of wheelchairs in Japan have witnessed a compound annual growth rate of 12.2% from 2016 to 2020. Projections indicate that this growth rate is expected to further escalate to a remarkable 21.3% over the next five years. Considering China and Japan’s status as pivotal markets for JinMed, these prospects highlight substantial opportunities for advancement.

According to the company’s prospectus and recent disclosures, JinMed is actively expanding its sales channels and business scope. On one hand, it is proactively expanding its research and development efforts, further establishing its presence in the wheelchair market segment. This includes the development of a new generation of ultra-lightweight portable electric wheelchairs, thereby enhancing the market competitiveness of its core products. On the other hand, the company has also expressed its intention to strengthen sales in both European and American markets. Furthermore, it has embarked on ventures related to developing shared wheelchair-related infrastructure and other shared medical products, breaking away from solely selling shared wheelchairs to customers as done previously. Additionally, leveraging its strengths, the company is diversifying into various businesses such as domestic elderly electric mobility vehicles, intelligent bathing products, beauty products, and respiratory devices.

JinMed’s interim report for this year has successfully overcome the challenges posed by external factors. With the further expansion of the wheelchair market and diversification of business development, there exists immense potential for revenue growth. Given the high expectations for an increase, the company’s high valuation is a justified reflection of its performance.

ONERHT Foundation Charity Golf 2023 raises more than S$400,000 for disadvantaged groups

SINGAPORE, Oct 9, 2023 – (ACN Newswire) – ONERHT Foundation Ltd (“Foundation”), the corporate social responsibility arm of RHTLaw Asia LLP and the RHT Group of Companies (collectively, “ONERHT”), successfully raised more than S$400,000 for disadvantaged groups with the support of generous donors and sponsors at the Foundation’s Charity Golf 2023 event.

Mr Azman Jaafar, Managing Partner of RHTLaw Asia, Mr Erwan Barre, Board Director of ONERHT Foundation, Ms Kaylee Kwok, Chairman of ONERHT Foundation, Guest-of-Honour Mr Gan Kim Yong, Minister for Trade and Industry, Mr Ho Peng Kee, Patron of ONERHT Foundation, and Mr Bernard Tay, Mr Jayaprakash Jagateesan, Mr Yang Eu Jin, Board Directors of ONERHT Foundation. [L-R]

Ms Kaylee Kwok, Chairman of ONERHT Foundation, said, “We continue to believe in the power of collective efforts with the support of the Foundation’s generous donors and sponsors to make a difference and drive positive change in the community. We remain committed to purposeful growth with philanthropy across the Foundation’s four core pillars of education, environment and sustainability, disadvantaged groups, as well as arts and sports.”

More than 170 golfers participated in the charity golf event held over two days on 29 September and 6 October at Orchid Country Club and Sentosa Golf Club respectively. The event culminated with a gala dinner attended by Guest-of-Honour, Minister for Trade and Industry Mr Gan Kim Yong, and more than 200 guests.

The Foundation, a registered charity and grant-making philanthropic organisation, collaborates with charitable organisations to support meaningful programmes that address various community needs in Singapore. Funds raised from this year’s charity golf event, now in its 8th edition, will provide crucial support to a range of beneficiaries, including:

· PAP Community Foundation Sparkle Care Centres

· Life Community Services Society

· Singapore Cancer Society

· Singapore Road Safety Council

Mr Jayaprakash Jagateesan, ONERHT Foundation Board Director and AlDigi Group Chief Executive Officer, said, “We believe that sustainable businesses must go beyond seeking profits to be a force for good in society. Philanthropy is not just an option; it’s a responsibility for companies to contribute to the well-being of the communities they operate in. ONERHT’s Specialised Group, a proud supporter of the Foundation’s charity golf event, continues to uphold its commitment to supporting meaningful causes for the community.”

Since its inception in 2015, the Foundation has raised closed to S$5 million with the support of its donors and sponsors for more than 30 charitable organisations.

ONERHT Foundation Ltd

A Singapore registered charity and grant-making philanthropic organisation, ONERHT Foundation Ltd (“Foundation”) enables RHTLaw Asia LLP and the RHT Group of Companies (collectively, “ONERHT”) to do right and do good through various charitable endeavours.

Set up by ONERHT in 2015, the Foundation was registered as a Singapore charity by the Commissioner of Charities and a grant-making philanthropic organisation by the Inland Revenue Authority of Singapore on 16 September 2016 and 28 November 2016 respectively.

The Foundation seeks to establish, inspire and encourage the right philanthropic culture among the corporate and legal fraternity of giving back to the community in a focused, hands-on and meaningful manner. Since its inception, the Foundation has raised closed to S$5 million to support more than 30 beneficiaries involved in education, the environment and sustainability, disadvantaged groups as well as the arts and sports. For more information, please visit www.onerht.foundation

ONERHT

ONERHT is an integrated multidisciplinary platform of professional and specialist services. Following the establishment of RHTLaw Asia in 2011, its founding team developed a second engine of growth through the RHT Group of Companies, an independent ecosystem of professional services, associated companies and networks, complementing RHTLaw Asia’s full service legal offerings.

The Specialised Group within ONERHT represents its investments into various business partnerships to develop cutting edge solutions for clients. These include specialist services and platforms across Web 3.0 Digital Economy, Wealth Advisory, Fund & Asset Management, Valuation & Advisory, Investor Relations and Events & Training.

For media enquiries, please contact: Elliot Siow / elliot.siow@rhtgoc.com / +65 8375 0417

ACROMETA’s Life Science Incubator (LSI) Signs Agreement with Ho Bee Land subsidiary to operate Co-Working Laboratory

SINGAPORE, Oct 6, 2023 – (ACN Newswire) – ACROMETA Group Limited (“ACROMETA”, or the “Company” and together with its subsidiaries, the “Group”), an established specialist engineering service provider in the field of controlled environments serving mainly the healthcare, biotechnology, pharmaceutical, research and academia sectors, today announced that its 70% owned subsidiary company Life Science Incubator Pte Ltd (“Life Science Incubator” or “LSI”) has entered into a Management Agreement (the “MA”) with HB Universal Pte Ltd, a subsidiary of Mainboard-listed Ho Bee Land Limited.

The MA engages LSI to operate and manage a co-working laboratory centre at Elementum, One-North, a building in the heart of Singapore’s biomedical industry district. The MA is for an initial period of six (6) years with an option to renew the MA for a further six (6) years by mutual agreement.

The MA engages LSI to operate, manage, promote and market the co-working laboratory centre; and to provide management and consultancy services for the business. The proposed project will triple the size of LSI’s co-working laboratory space operations in Singapore. With the expanded space, the operations at Elementum will be able to attract companies that require larger Research and Development (“R&D”) space, as well as enable existing LSI customers who want to expand their R&D activities to do so.

The MA follows on the heels of LSI’s recent expansion of its co-working lab space business. On 6 April 2023, Acrometa announced to SGXNet that Life Science Incubator signed an MOU with a renowned German commercial property group to be the anchor tenant for its planned Brisbane co-working laboratory space project. On 21 March 2023, AcroMeta announced that it had signed an MOU with a Thailand industrial waste disposal company for the construction and operation of a laboratory for the testing and certification of solid waste and sludge. The construction of the laboratory would be done by Acrometa’s wholly-owned subsidiary Acromec Engineers, and LSI would operate the laboratory; with an option for joint ownership.

Mr Levin Lee Keng Weng, ACROMETA’s Executive Chairman, commented: “Biomedical sciences is an integral part of Singapore’s future economy with its focus on high value-add industries. Co-working laboratory spaces allows SMEs and startups to kickstart their R&D without incurring initial high CAPEX. There is a rising number of SMEs and startups needing co-working laboratory spaces with specialized infrastructure to conduct their R&D to bring their innovative products to the market. That is where LSI comes in.”

Mr Lee added, “Having a working partnership with Ho Bee Land, a well-known and established property developer, would solidify the LSI brand of co-working laboratory spaces. This will position us for international expansion of the LSI brand that we are planning, as there is demand for co-working laboratory space in major cities and industrial hubs globally.”

Reference:

https://links.sgx.com/1.0.0/corporate-announcements/SC90A0YKN02PFDZS/28c5ad55d8d648b608d9fb066a8c4a834c84667232efed4f6ad1c5fc5f46e3c2

About ACROMETA Group Limited (SGX Stock Code:43F)

ACROMETA (Previously known as ACROMEC Limited) is an established specialist engineering services provider with more than 25 years of experience in the field of controlled environments.

The Group has, over the years, acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities and cleanrooms.

ACROMETA’s business is divided into three main business segments: (i) Engineering, procurement, and construction services, specialising in architectural, and mechanical, electrical, and process works within controlled environments; (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure. (iii) Co-Working Laboratory business; currently operates 6,500 square feet of co-working laboratory space at The German Centre in Singapore, serving SMEs and startups.

The Group mainly serves the healthcare, biotechnology, pharmaceutical, research and academia, and electronics sectors. ACROMETA’s customers include hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies.

The Company has been listed on the Catalist board of the Singapore Exchange since 2016. For more information, please visit www.acrometa.com.

Media and Analysts Contact:
ACROMETA Group Limited
Ms. Cheah Lai Min
Chief Financial Officer
Tel: +65 6415 0574
Email: laimin.cheah@acrometa.com

Waterbrooks Consultants Pte Ltd
Mr. Wayne Koo
Tel: +65 6958 8008 / +65 9338 8166
Email: wayne.koo@waterbrooks.com.sg
Email: query@waterbrooks.com.sg

This media release has been reviewed by the Company’s Sponsor, Evolve Capital Advisory Private Limited (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “Exchange”), and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr. Jerry Chua, 138 Robinson Road, #13-02 Oxley Tower, Singapore 068906, jerrychua@evolvecapitalasia.com.

Medi Lifestyle Limited Elevates Wound Care Innovations at Global Conference

KUALA LUMPUR, Oct 6, 2023 – (ACN Newswire) – Medi Lifestyle Limited (“Medi Lifestyle” or the “Group”), a renowned Singapore-listed frontrunner in healthcare innovation, is please to participate as an exhibitor at the prestigious “D-Foot International, Apadlp & 5th Global Wound Conference 2023” themed “Woundbusters The Legacy”. The much-anticipated event takes place from the 6th to the 8th of October 2023, at the Sunway Pyramid Convention Centre in Selangor, Malaysia.

Dato' Ken Low, Executive Director and Chief Executive Officer of Medi Lifestyle — Dato’ Ken Low, Executive Director and Chief Executive Officer of Medi Lifestyle

This significant conference has garnered the support of esteemed organisations and authorities, including the Ministry of Health Malaysia, Hospital Kuala Lumpur, Asian Wound Care Association, Sunway Medical Centre (Sunway City), Malaysia Society of Wound Care Professionals, and other respected entities. As such, attendees are engaged with a diverse group of professionals, from industry experts, specialists, and scientists to doctors specialising in wound management and chronic wound treatment.

Medi Lifestyle's Booth at — Medi Lifestyle’s Booth at “D-Foot International, Apadlp & 5th Global Wound Conference 2023”

Beyond its evident prestige, this conference plays an indispensable role in advancing the wound care industry. It presents a golden opportunity for professionals to share insights, latest research, and groundbreaking techniques. For the general public, it signifies hope and progress in wound care, as breakthroughs here can lead to improved treatments and quicker recovery times. For Medi Lifestyle, this platform offers a chance to showcase their innovations, solidifying their position at the forefront of the industry.

A highlight of Medi Lifestyle’s participation is the introduction of its two paramount products: high-purity exosomes and cell-related products. For the uninitiated, exosomes are tiny vesicles or cell-derived nanoparticles that play a vital role in intercellular communication. The Group prides itself on the high-purity of its exosomes, ensuring they meet clinical standards, surpassing mere cosmetic grade.

The therapeutic potential of these high-purity exosomes extends to serving as or aiding in anti-inflammatory responses, promoting effective skin graft reactions, and contributing to skin rejuvenation.

Dato’ Ken Low, Executive Director and Chief Executive Officer of Medi Lifestyle expressed gratitude for the opportunity to participate, stating, “We are deeply grateful for this opportunity not only to showcase our products but also to engage with esteemed industry players, authorities, and government agencies. This gathering is invaluable for knowledge exchange and expertise sharing. Through these interactions, we believe the transformative benefits of our innovations for the public will become even more evident.”

Medi Lifestyle cordially invites all attendees to visit their exhibit to gain a deeper understanding of their groundbreaking products and the future of wound care.

With registered offices and clinics extending their reach to Petaling Jaya, Malaysia, Medi Lifestyle continues to break barriers and redefine healthcare for the future.

Medi Lifestyle Ltd: https://www.medi-lifestyle.com/

Could Vegan Pet Food Help Save the Planet?

WINCHESTER, ENGLAND, Oct 6, 2023 – (ACN Newswire) – Studies show plant-based diets lower greenhouse gas emissions (GHGs), and use less land and water. Food energy savings mean more people can be fed. This has triggered calls for vegan diets – but not for our pets. Yet a new major study published in leading scientific journal PLOS ONE has demonstrated very large environmental benefits associated with nutritionally-sound vegan diets – for dogs and cats, as well as people.

After analysing pet food ingredients in detail, Veterinary Professor Andrew Knight calculated that the world’s dogs and cats consume seven billion land animals annually, as well as billions of fish. If all the world’s dogs went vegan, it would save more GHGs than those emitted by the UK, land larger than Mexico, and could feed 450 million additional people – more than the entire EU. If all the world’s cats went vegan, it could feed 70 million additional people – more than the entire UK. And if all the world’s people went vegan, it would save more GHGs than all those emitted by the entire EU, land larger than Russia – the world’s largest country, combined with India, and would feed around 5.3 billion additional people – two thirds of the Earth’s current population.

Until recently, vegan diets were not seriously considered for dogs and cats – who are biologically omnivores and carnivores respectively. In the last two years however, many new vegan pet foods have been developed by companies using plant-based ingredients supplemented with vitamins, amino acids and minerals, to ensure all necessary nutrients are included. New studies have shown good health and behavioural outcomes for dogs and cats using such diets. There are now 9 such studies in dogs, and 3 in cats. The most recent very large-scale study showed positive health outcomes in vegan cats, following a similar canine study in 2022. These have driven rapid growth with the vegan dog food market valued at USD 14 billion by 2023, and expected to reach USD 26 billion by 2033.

Said Professor Knight, “This is game-changing. We’ve long known that plant-based diets are better for the planet, but have not seriously considered pet food. However, pet food clearly has profound environmental impacts. Conversely, very large environmental benefits can be achieved by nutritionally-sound vegan pet food. Large-scale studies have also shown that health outcomes for both dogs and cats are as good or better. And studies of feeding behaviour have demonstrated that average dogs and cats enjoy vegan pet foods as much as those made from meat.”

He concluded: “Pet owners who care about the environment or their animals’ health should consider nutritionally-sound vegan pet food. However, to safeguard health, it is important that people feed only commercial diets labelled as nutritionally complete, produced by reputable companies with good standards.”

Contact Information
Andrew Knight
Veterinary Professor of Animal Welfare
andrew.knight@winchester.ac.uk

Related image

ZeptoMetrix Awarded in Vitro Diagnostic Regulation (IVDR) Certification

BUFFALO, NY, Oct 3, 2023 – (ACN Newswire) – ZeptoMetrix® is pleased to announce it has been awarded an IVDR Quality Management System certificate from British Standards Institution BSI, NB 2797, one of the notified bodies under the new EU In Vitro Diagnostics Regulation (IVDR). This certificate applies to the majority of the current portfolio of CE marked ZeptoMetrix NATtrol™ quality control products that are the industry’s preferred brand for molecular diagnostic testing and are supplied ready-to-use as independent third-party quality control materials. With this significant certification step completed, ZeptoMetrix will focus on the implementation of updated product labelling over the next several months.

“ZeptoMetrix is delighted with our smooth and efficient transition to IVDR,” commented Glenn Harrall, Global Vice President of Quality, ZeptoMetrix. “This transition reflects ZeptoMetrix continuous investments in quality programs, regulatory compliance and demonstrates our ongoing quality commitment to our partners and customers.”

“Achieving this certification milestone is further demonstration of ZeptoMetrix’s commitment to supporting European clinical laboratories with reliable, innovative quality controls,” said Evangeline Gonzalez, President, ZeptoMetrix.

For more information on ZeptoMetrix and NATtrol products, visit www.zeptometrix.com.

About ZeptoMetrix®

ZeptoMetrix, an Antylia Scientific company, is an established industry leader in the design, development, and delivery of innovative, quality solutions to the infectious disease diagnostics market. Our expertise and abilities in molecular diagnostics, including external quality controls, verification panels, proficiency panels, customized and OEM products/services, have set the industry standard for performance and reliability and make ZeptoMetrix the preferred choice for independent third-party quality control materials.

Contact Information
Andrew Zenger
Global Product Manager
andrew.zenger@antylia.com
(716) 715-7417

HanchorBio Announces First Patient Dosed in the Phase 1 Multi-Regional Clinical Trial of HCB101

SAN FRANCISCO, CA and TAIPEI, TAIWAN, Oct 3, 2023 – (ACN Newswire) – HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from different solid tumors or hematological malignancies with significant unmet medical needs, today announced that the first patient has been dosed in a Phase 1, multi-regional, multi-center clinical trial (ClinicalTrials.gov ID: NCT05892718). The trial aims to evaluate the safety, tolerability, pharmacodynamics, and anti-tumor activity of HCB101 in patients with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma.

“The dosing of the first patient with HCB101 marks another major milestone in evaluating the potential benefit of HCB101 for these patient populations,” said Scott Liu, Ph.D., Founder, Chairman, and Chief Executive Officer of HanchorBio. “Based on the preclinical head-to-head comparison studies, HCB101 repeatedly demonstrated superior efficacy and excellent safety profiles in comparison with several similar biologics currently being investigated in clinical trials targeting the same SIRPα-CD47 pathway. I am immensely proud of the teamwork that has brought our differentiated program to this point with only 2.6 years from the Company’s inception to IND and now first-patient-in. HanchorBio is dedicated to discovering and developing immunotherapies to overcome the inadequacies of PD-1/L1 therapies with our proprietary FBDB™ technology platform.”

“There is an urgent need for new treatment options for patients with cancer, particularly those who cannot tolerate currently available therapies,” commented Jason Tsai, M.D., M.S., Chief Medical Officer of HanchorBio. “Through blockade of the SIRPα-CD47 pathway, HCB101 brings additional armament to fight cancer. Our goal is to bring transformative treatment options for patients with cancer by developing HCB101 as a foundational innate immunity checkpoint immunotherapy and open the door to innate-adaptive combination immuno-oncology therapy.”

HCB101 is an engineered fusion protein using the Company’s proprietary Fc-based designer biologics (FBDB™) technology platform that blocks the “do not eat” signal from the SIRPα-CD47 pathway, which inhibits the ability of macrophages to engulf and destroy cancer cells. Preclinical studies have shown that HCB101 has anti-tumor activity across a wide range of solid tumors and hematological malignancies. Unlike other similar agents, HCB101 exhibits excellent safety profiles in the repeat-dose cynomolgus monkey toxicology studies, as no abnormality of RBC or platelet levels were observed, with a potential as the best-in-class anti-SIRPα-CD47 immunotherapy.

HanchorBio owns worldwide commercial rights to HCB101.

About HCB101

Discovered through a structure-guided protein design and engineering supplemented with relevant screening technologies, HCB101 is an engineered extracellular domain of SIRPα fused to the Fc region of IgG4. HCB101 triggers potent phagocytic activity of the macrophages by primarily blocking the “do not eat” signal between macrophages and tumor cells. Based on the extensive in-vitro and in-vivo preclinical data, HCB101 is potentially a safer and more potent biologic than the anti-CD47 monoclonal antibodies and SIRPa fusion proteins currently being investigated in clinical trials. Furthermore, quantitative RNA transcriptional analysis indicated that HCB101 triggered distinct gene expression profiles inside the tumor and in the tumor microenvironment compared to other relevant clinical candidates, suggesting that HCB101 might exhibit unique mechanisms of action. Using HCB101 as the foundation, our pipeline includes other arms targeting both adaptive and innate immunity to help revolutionize the treatment of patients with cancer and other debilitating diseases.

About Multi-Regional Clinical Trial of HCB101 (NCT05892718)

HCB101-101 is a multi-regional, multi-center, open-label, dose-finding, first-in-human (FIH) study of adults with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma in the United States and Taiwan. The purposes of the study are to evaluate the safety, tolerability, pharmacokinetics, and clinical anti-tumor activity of HCB101 via intravenous injections. HCB101-101 has already received IND clearance by the U.S. FDA in April 2023 and the Taiwan FDA in July 2023.

About HanchorBio

Based in Taipei, Shanghai, and San Francisco Bay Area, HanchorBio is a global clinical-stage biotechnology company focusing on immuno-oncology. The Company is led by an experienced team of pharmaceutical industry veterans with a proven track record of success in biologics discovery and global development to transcend current cancer therapies. Committed to reactivating the immune system to fight against diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to overcome the current inadequacies of anti-PD1/L1 immunotherapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs.

For more information, please visit: www.HanchorBio.com or follow us on LinkedIn at www.linkedin.com/company/hanchorbio-inc

Contact Information
Scott Liu, Founder, Chairman and CEO, scott_liu@hanchorbio.com
Yi Du, Sr. Director of Business Development, yi_du@hanchorbio.com